89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesGlobeNewsWire • 02/27/25
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?Zacks Investment Research • 02/20/25
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a BetZacks Investment Research • 02/03/25
89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/29/25
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 01/27/25
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024GlobeNewsWire • 11/15/24
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewsWire • 11/13/24
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024GlobeNewsWire • 10/15/24
89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor ConferenceGlobeNewsWire • 09/30/24
89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality OfficerGlobeNewsWire • 09/16/24
Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASHInvestors Business Daily • 06/05/24
89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver CongressGlobeNewsWire • 05/22/24